Zanubrutinib Oral Product
Phase 2
Zanubrutinib Oral Product is one of 52 therapeutic programs targeting Chronic Lymphocytic Leukemia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
51
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
87 competitors in Chronic Lymphocytic Leukemia
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 3
Gazyva
RochePhase 3
Calquence
AstraZenecaPhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Brukinsa
BBeOne Medicines
Phase 3
Keytruda
Merck & Co.Phase 3
Adcetris
PfizerPhase 3
Beqalzi
BBeOne Medicines
Phase 3
Campath
GGenzyme, a Sanofi Company
Phase 2
Nemtabrutinib
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Zanubrutinib Oral Product. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- PPETHEMA Foundation